Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 2
1992 2
1994 1
1995 2
1996 2
1997 2
1998 1
1999 5
2001 3
2002 6
2003 3
2004 10
2005 6
2006 4
2007 2
2008 3
2009 3
2010 4
2011 7
2012 6
2013 5
2014 1
2015 7
2016 6
2017 8
2018 8
2019 7
2020 2
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 28076247

116 results
Results by year
Filters applied: . Clear all
Page 1
5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI).
Mospan GA, Wargo KA. Mospan GA, et al. J Am Board Fam Med. 2016 Nov 12;29(6):654-662. doi: 10.3122/jabfm.2016.06.160065. J Am Board Fam Med. 2016. PMID: 28076247 Free article.
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. Peterson J, et al. Urology. 2008 Jan;71(1):17-22. doi: 10.1016/j.urology.2007.09.002. Urology. 2008. PMID: 18242357 Clinical Trial.
A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. Klausner HA, et al. Curr Med Res Opin. 2007 Nov;23(11):2637-45. doi: 10.1185/030079907x233340. Curr Med Res Opin. 2007. PMID: 17880755 Clinical Trial.
A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. Connolly LE, et al. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01989-17. doi: 10.1128/AAC.01989-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29378708 Free PMC article. Clinical Trial.
Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
Henry DC, Nenad RC, Iravani A, Tice AD, Mansfield DL, Magner DJ, Dorr MB, Talbot GH. Henry DC, et al. Clin Ther. 1999 Jun;21(6):966-81. doi: 10.1016/s0149-2918(99)80018-6. Clin Ther. 1999. PMID: 10440621 Clinical Trial.
Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T, van Mens SP, van Nieuwkoop C, Geerlings SE, Hoepelman AIM, Bonten MJM. Ten Doesschate T, et al. BMC Infect Dis. 2018 Dec 5;18(1):626. doi: 10.1186/s12879-018-3562-2. BMC Infect Dis. 2018. PMID: 30518334 Free PMC article. Clinical Trial.
Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
Wagenlehner F, Nowicki M, Bentley C, Lückermann M, Wohlert S, Fischer C, Vente A, Naber K, Dalhoff A. Wagenlehner F, et al. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02317-17. doi: 10.1128/AAC.02317-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29339395 Free PMC article. Clinical Trial.
Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.
Naber KG, Allin DM, Clarysse L, Haworth DA, James IG, Raini C, Schneider H, Wall A, Weitz P, Hopkins G, Ankel-Fuchs D. Naber KG, et al. Int J Antimicrob Agents. 2004 Jun;23(6):596-605. doi: 10.1016/j.ijantimicag.2003.12.017. Int J Antimicrob Agents. 2004. PMID: 15194131 Clinical Trial.
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
Armstrong ES, Mikulca JA, Cloutier DJ, Bliss CA, Steenbergen JN. Armstrong ES, et al. BMC Infect Dis. 2016 Nov 25;16(1):710. doi: 10.1186/s12879-016-2057-2. BMC Infect Dis. 2016. PMID: 27887579 Free PMC article. Clinical Trial.
Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial.
Ren H, Li X, Ni ZH, Niu JY, Cao B, Xu J, Cheng H, Tu XW, Ren AM, Hu Y, Xing CY, Liu YH, Li YF, Cen J, Zhou R, Xu XD, Qiu XH, Chen N. Ren H, et al. Int Urol Nephrol. 2017 Mar;49(3):499-507. doi: 10.1007/s11255-017-1507-0. Epub 2017 Jan 20. Int Urol Nephrol. 2017. PMID: 28108978 Free PMC article. Clinical Trial.
116 results
Jump to page
Feedback